恩度联合化疗治疗中晚期非小细胞肺癌的疗效及相关因素分析  

Multivariate analysis of endostar combined with chemotherapy efficacy in patients with advanced non-small cell lung cancer

作　　者：凌华晃[1] 黄锡梅[1] 李涛[1] 吴祥成[1] 蔡茂德[1] 

机构地区：[1]广东省高州市人民医院化疗科,高州525200

出　　处：《中国肿瘤临床与康复》2015年第3期295-297,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨影响恩度联合化疗治疗中晚期非小细胞肺癌(NSCLC)疗效的相关因素。方法回顾性分析2008年1月至2012年12月接受治疗的60例中晚期NSCLC患者的临床资料,根据肿瘤近期疗效评价标准,分为试验组(34例)和对照组(24例)。试验组为完全缓解和部分缓解的患者,对照组为稳定和肿瘤进展的患者,比较两组患者的相关因素。结果单因素方差分析显示,TNM分期、T分期和肿瘤体积与恩度联合化疗疗效有关(均P<0.05)。Logistic分析显示,TNM分期、T分期和肿瘤体积为影响恩度联合化疗疗效的独立因素。结论 TNM分期、T分期和肿瘤病灶体积是恩度联合化疗治疗中晚期NSCLC疗效的影响因素。Objective To investigate the factors of endostar combined with chemotherapy efficacy in patients with advanced non-small cell lung cancer. Methods Retrospective analysis of clinical data of60 patients with advanced non-small cell lung cancer were collected and divided into observation group and control group from January 2008 to December 2012. Observation group include patients with complete response（ CR） and partial response（ PR）,while the control group include patients with stable disease（ SD）and progressive disease（ PD）. Related factors of both groups were compared. Results The relevant factors influencing endostar combined with chemotherapy efficacy were TNM stages,T stage and volume of tumor lesion by virtue of ANOVA. The efficacy of first admission with clinical stage ≤ IIIB was 4. 5 times of that of stage IV by logistic analysis. The efficacy of first admission with clinical stage T1 ~ T2 was 3. 6 times of that of stage T3 ~ T4. The efficacy of first admission with tumor lesion volume ≥120 cm3 was 6. 0 times of that of tumor lesion volume 120 cm3. Conclusion TNM stage,T stage and tumor lesion volume are factors for efficacy of endostar combined with chemotherapy in patients with advanced non-small cell lung cancer.

关 键 词：癌 非小细胞肺 恩度 治疗结果 因素分析 统计学 

分 类 号：R734.2[医药卫生—肿瘤]